Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference
December 21 2023 - 4:15PM
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its
participation in the 42nd Annual JPMorgan Healthcare Conference
taking place January 8 – January 12, 2024.
Lonnel Coats, Lexicon’s chief executive officer,
will make a company presentation at 10:30am PT / 1:30 pm ET on
Thursday, January 11th. Jeff Wade, Lexicon’s president and chief
financial officer, Tom Garner, Lexicon’s senior vice president and
chief commercial officer, and Craig Granowitz, M.D., Ph.D.,
Lexicon’s senior vice president and chief medical officer, will
also participate in the presentation.
A simultaneous webcast will be available in the
“Events” section of the Lexicon website at
www.lexpharma.com/events, and a recording of the webcast will be
available for two weeks following the original on-demand date.
About Lexicon
Pharmaceuticals
Lexicon is a biopharmaceutical company with a
mission of pioneering medicines that transform patients’ lives.
Through its Genome5000™ program, Lexicon scientists studied the
role and function of nearly 5,000 genes and identified more than
100 protein targets with significant therapeutic potential in a
range of diseases. Through the precise targeting of these proteins,
Lexicon is pioneering the discovery and development of innovative
medicines to safely and effectively treat disease. Lexicon is
commercially launching one of these medicines, INPEFA®
(sotagliflozin) in the United States, and has a pipeline of other
promising drug candidates in discovery and clinical and preclinical
development in neuropathic pain, diabetes and metabolism and other
indications. For additional information, please visit
www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking
statements,” including statements relating to Lexicon’s financial
position and long-term outlook on its business, growth and future
operating results, discovery and development of products, strategic
alliances and intellectual property, as well as other matters that
are not historical facts or information. All forward-looking
statements are based on management’s current assumptions and
expectations and involve risks, uncertainties and other important
factors, specifically including Lexicon’s ability to meet its
capital requirements, successfully commercialize INPEFA in heart
failure on the timeline and/or at the prices currently contemplated
or at all, conduct preclinical and clinical development and obtain
necessary regulatory approvals of INPEFA (in other indications),
LX9211 and its other drug candidates on its anticipated timelines,
achieve its operational objectives, obtain patent protection for
its discoveries and establish strategic alliances, as well as
additional factors relating to manufacturing, intellectual property
rights, and the therapeutic or commercial value of its drug
candidates. Any of these risks, uncertainties and other factors may
cause Lexicon’s actual results to be materially different from any
future results expressed or implied by such forward-looking
statements. Information identifying such important factors is
contained under “Risk Factors” in Lexicon’s annual report on Form
10-K for the year ended December 31, 2022 and other subsequent
disclosure documents filed with the Securities and Exchange
Commission. Lexicon undertakes no obligation to update or revise
any such forward-looking statements, whether as a result of new
information, future events or otherwise.
For Investor Inquiries:
Lisa DeFrancesco Lexicon Pharmaceuticals,
Inc. lexinvest@lexpharma.com
For Media Inquiries:
Alina CocuzzaLexicon Pharmaceuticals,
Inc.acocuzza@lexpharma.com
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Aug 2023 to Aug 2024